Get started
JOHNSON & JOHNSON CEDEAR EACH 15 REP 1 ORD SHSJJ

JOHNSON & JOHNSON CEDEAR EACH 15 REP 1 ORD SHS

11,850ARSD
−125−1.04%
At close at May 9, 22:29 GMT
ARS
No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

JNJ trade ideas

JNJ outperforming BUT M-pattern may retest 163/157 if 170 failsSo far JNJ is outperforming the SPY as staples are a defensive play during uncertain markets. But if JNJ fails to break above my 170 yellow zone (also BO of the black falling wedge) in the next few days then a retest of the 163 green support zone is next. 163 is also a 1.272 Fib zone & also a retest of the blue upchannel base. This is an ideal spot to end the M-pattern to start a new uptrend validating the blue upchannel. Although less probable for the near term, a retest of the 157 red zone may occur if the blue channel breaks as this is the upper side of a big red channel started in 2004. Not trading advice
NYSE:JNJLong
by xtremerider8
JNJ bullish scenario:The technical figure Pennant can be found in the US company Johnson & Johnson (JNJ) at daily chart. Johnson & Johnson is an American multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. The Pennant has broken through the resistance line on 23/05/2022, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 6 days towards 184.37 USD. Your stop loss order according to experts should be placed at 172.71 USD if you decide to enter this position. Johnson & Johnson is now working to spin off its consumer health division and after the company entered a series of settlements for its part in the opioid crisis. First-quarter metrics were mixed, but the company's medical devices business had few declines. Now, the Dow index stalwart expects $94.8 billion to $95.8 billion in 2022 sales. That no longer includes prior expectations for $3 billion to $3.5 billion in Covid vaccine sales. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
NLong
by legacyFXofficial
JNJ presenting a BUY LEVELNYSE:JNJ The Conservative Stop offers less exposition and a great Risk/Reward Ratio of 5 at the risk of being too tight .While the wide stop offers much more room for the trade at the expense of a lesser Risk/Reward Ratio around 3.5 . Whatever your style ,trading is a game of probabilities and the bulk of the profit if not all the significant profit is realised on a long serie of trades and not solely on a single trade . Results of any Individual trade shrink to insignificance when compared to the sum total of the long serie of trades . At the same time it is important to stick each time to your edge on the market in order to profit on the long term . Enthusiastically Brought to You by ManhattanStocks All Requests Suggestions and Remarks are Welcome
NLong
by manhattanstocks
JNJ BO W4 running flat; ext W5 of V ends in 2023 bef recessionIn the bigger picture in this weekly chart, JNJ BO of the big multi-year red upchannel & retested it several times in 2021 when JNJ was making wave 4 of V which is a running flat consolidation lasting the whole of 2021 bottoming in 29 Nov2021. Notice that the bigger wave IV is an expanded flat (megaphone pattern) bottoming in covid low. Now it has completed wave 4 of V & has successfully broke out of this wave 4 running flat consolidation breaking the 174 resistance. First attempt was in August of 2021, a false BO (bulltrap) before it crash down to complete wave 4 & also again retest the big red upper upchannel for the 5th time. (It was retested a total of 7 times) The whole wave V was pretty much in the form of an upchannel. JNJ now doing the final wave 5 of V. This looks like an extended wave 5 which will end sometime in 2023 before recession. JNJ belongs to XLP staples group & has recently been outperforming SPX as it is a defensive stock in times of market uncertainty. Not trading advice
NLong
by xtremerider8
$JNJ to make new ATH's$JNJ looks primed and ready to make new all-time highs this week. JNJ is in an ascending channel and based on RSI staying above 50 combined with MACD building and not near its relative "max" (about 4.44), this stock looks like it has legs. I think it is about to break through resistance relatively easily. With this risky, volatile, day-to-day market, healthcare will be one of the sectors to hide out in and have relative stability and more potential for upside. A good defensive place to be that can be a lucrative trade/investment. JNJ is the best-in-breed, blue-chip with a solid diversified portfolio and potential for capital appreciation alongside a 2.40% dividend yield. Healthcare is going to be a killer sector to be in if you have about a 5-year time horizon. During tightening cycles, tech, energy, and utilities do well, but I do see healthcare being one of the need-to-be in sectors going forward.
NLong
by EBITDAtiger
Johnson and Johnson at Key Resistance? Johnson and Johnson - Short Term - We look to Sell at 176.93 (stop at 178.95) Previous resistance located at 176.00. We look to sell rallies. This provides an excellent risk/reward opportunity to fade the current bullish move. Although the anticipated move lower is corrective, it does offer ample risk/reward today. Our profit targets will be 172.09 and 168.20 Resistance: 176.00 / 180.00 / 200.00 Support: 170.00 / 165.00 / 155.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading . The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NShort
by Saxo
Johnson and Johnson loosing ground. JNJImmediate targets at 165, 156, 149. Invalidation at 194. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NShort
by Rykin_Capital